Who is sponsoring NCT01454271?

NCT01454271 is sponsored by Societe ACTIVBIOMAT.

What drugs are being tested in NCT01454271?

Interventions in NCT01454271: Total Hip Arthroplasty Replacement.

What condition does NCT01454271 study?

NCT01454271 studies Hip Arthroplasty Replacement.

Is NCT01454271 still recruiting?

NCT01454271 is currently withdrawn. Last updated 14 August 2018.

Last reviewed 2018-08-14 · How we verify

NCT01454271

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Follow up Study of Patients Undergoing Total Hip Arthroplasty CERAFIT® Grafted With Poly Sodium Styrene Sulfonate

Withdrawn Phase 1, PHASE2 Last updated 14 August 2018

What this trial tests

Phase 1, PHASE2 trial testing Total Hip Arthroplasty Replacement in Hip Arthroplasty Replacement. Withdrawn.

Quick facts

Lead sponsor	Societe ACTIVBIOMAT
Phase	Phase 1, PHASE2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Sites	1 location across France

Drugs / interventions tested

Total Hip Arthroplasty Replacement

Conditions studied

Hip Arthroplasty Replacement — all drugs for Hip Arthroplasty Replacement →

Sponsor

Societe ACTIVBIOMAT

Who can join

Adults 18 to 75, any sex, with Hip Arthroplasty Replacement. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The risk of infection after primary Total Hip Arthroplasties (THA)is generally estimated to be less than 1% but remains a severe and costly complication, source of morbidity and even mortality. The "biofilm" forms very early after the bacterial contamination of the prosthesis and poses a number of clinical challenges due to his resistance to immune defence mechanisms and antibiotics. Preventive strategies are needed. The poly sodium styrene sulfonate (pNaSS) is a bioactive polymer. In vitro and in vivo studies showed that poly sodium styrene sulfonate grafted on titane surfaces reduce significantly the bacterial adhesion. They also proved his biocompatibility and osseous-integration.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hip Arthroplasty Replacement

Currently open trials in the same condition.

NCT07392515 — Cognitive and Physical Recovery After Hip Fracture in Frail Patients Using Digital Rehabilitation Technology · NA · recruiting
NCT07110324 — Characteristics of Persistent Pain Composition Following Total Hip or Knee Arthroplasty: a Descriptive Study · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01454271 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Societe ACTIVBIOMAT
Last refreshed: 14 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01454271.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing